Korea’s Local Pharmas Unite to Strengthen mRNA Vaccine Production

by Kathy Huang
Share To

Since the South Korean government officially announced plans to develop its own mRNA vaccine by 2022, many Korean pharma companies have been following up.


Korea’s First Manufacturer of mRNA Vaccine

As one of the leading pharmaceutical companies in Korea, Samsung Biologics announced the agreement with Moderna for fill-finish manufacturing of mRNA-1273 on May 22nd, making it the first Korean company to take part in the mRNA vaccine production.

Under the contract with Moderna, Samsung Biologics plans to add an mRNA vaccine production line at its facility in Songdo by early 2022, which is also part of Samsung Biologics’s long-term strategy to expand its business portfolio.


Alliance Within Local Pharmas

While Samsung Biologics takes the lead in production for Moderna’s mRNA vaccine, several Korean pharma companies are uniting to localize their power.

Hanmi Science and GeneOne Life Science, two of Korea’s local vaccine developers, announced on June 1st that they entered into the collaboration to ensure large manufacturing of mRNA shots.

On the same day, another Korea’s pharma company, ST Pharm made the announcement that it would join the camp by developing a lipid nanoparticle (LNP)-based COVID-19 mRNA vaccine. The lipid particles can activate immune cells, according to which ST Pharm expects the technology would enhance the efficacy of the existing mRNA vaccine.

Related Article: Samsung Biologics to Produce mRNA Vaccine Ingredients in Songdo Facility


© All rights reserved. Collaborate with us:
Related Post
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
Taiwan Biotech Delegation Leads International Exchange with Phoenix Biotech Community and Mayo Clinic
BIO 2024 Sets the Stage for Taiwan’s Biotech Industry to Shine
GV Innovation High-Value Niche Market Transformation Project
ASCO 2024: Covering Skin Cancer, Bispecific Antibody Treatment, TIGIT-Targeted Drugs, Radiotherapy and More
Major Cancer Research Publications at the 2024 American Society of Clinical Oncology Annual Meeting
Eli Lilly Breaks Records with $9B Total Investment in Indiana Weight-loss Drug Expansion
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
Scroll to Top